GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

Today
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Arvaya Healthcare Ltd
Board Meeting approved the acquisition of the SIGPL.
M&A ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 11 Jul 2026, 02:56 PM IST  ·  BSE ID: 2536e496-e278-4673-81ba-798dda6dec1e
View Original BSE Filing (PDF)
💡
In Simple Terms
Arvaya Healthcare is buying another company, Sushodha Institute of Gastroenterology, for Rs. 15.48 Crore by issuing its own shares.
🤖 AI Summary
  • Arvaya Healthcare's Board approved acquiring 100% equity of Sushodha Institute of Gastroenterology Private Limited (SIGPL).
  • The acquisition of 1,84,374 SIGPL equity shares is for a total of Rs. 15,48,74,160/-.
  • Consideration will be discharged by issuing up to 38,71,854 Arvaya Healthcare shares at Rs. 40/- each.
  • Board approved a Rights Issue of Specified Securities for a maximum amount not exceeding Rs. 210 Crores.
  • The company will change its registered office from Assam to Maharashtra, subject to regulatory approvals.
🔢 Key Numbers — exact figures from BSE filing, not rounded
SIGPL Equity Shares Acquired
1,84,374 Equity Shares
Total Purchase Consideration for SIGPL
Rs. 15,48,74,160/-
Acquisition Price per SIGPL Share
Rs. 840/-
Arvaya Healthcare Shares Issued for Acquisition
38,71,854 Equity Shares
Issue Price per Arvaya Healthcare Share (Acquisition)
Rs. 40/-
Maximum Amount for Rights Issue
Rs. 210 Crores
🏢 How This Affects the Company
📈
Business Impact
This acquisition integrates 100% of Sushodha Institute of Gastroenterology Private Limited into Arvaya Healthcare, potentially expanding its healthcare service offerings.
💰
Financial Impact
The transaction will increase Arvaya Healthcare's equity base by issuing up to 38,71,854 new shares, valued at Rs. 15,48,74,160/-. A Rights Issue of up to Rs. 210 Crores is also approved to raise additional funds.
⚙️
Operational Impact
The change in registered office from Assam to Maharashtra will relocate the company's administrative base, subject to necessary approvals.
⚠️
Risk Impact
The acquisition and Rights Issue are subject to customary conditions, including shareholders' approval and other regulatory approvals, which introduce execution risk for these initiatives.
👥 What This Means For Shareholders
Action Required
Shareholders will be required to vote on the acquisition, preferential issue, and other resolutions via a postal ballot process.
👤
Who Is Affected
Shareholders of record on Friday, July 10, 2026, are affected for E-voting. Existing shareholders may subscribe to the Rights Issue.
🔍
Management Signal
Management intends to expand the company's business through acquisition and strengthen its capital base through new share issuance and a Rights Issue.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Shareholder approval for acquisition and preferential issue via postal ballot.
Further updates on the Rights Issue terms and record date.
Completion of registered office change from Assam to Maharashtra.
MEDIUM RISK Both the acquisition and rights issue are subject to shareholder and regulatory approvals, which introduces execution risk.
💡 Investor Takeaway
Arvaya Healthcare Board approved the acquisition of 100% equity of SIGPL for Rs. 15,48,74,160/- by issuing shares at Rs. 40/- each. A Rights Issue up to Rs. 210 Crores was also approved, both subject to shareholder and regulatory approvals.
⚖️ Strengths & Concerns

✅ Positives

  • Acquisition of 100% equity of SIGPL provides full control and integration of the target entity's business.
  • Fundraising up to Rs. 210 Crores via Rights Issue can strengthen the company's capital base for future growth.

⚠️ Concerns

  • The acquisition and Rights Issue are subject to shareholder and regulatory approvals, delaying completion.
  • Consideration for acquisition is solely through issuance of Arvaya Healthcare shares, potentially diluting existing equity.
📅 Company Track Record
Arvaya Healthcare Ltd (formerly Bijoy Hans Limited) had a board meeting on July 11, 2026, to consider this acquisition and a capital raise, as informed to BSE on July 6, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What did Arvaya Healthcare's Board approve on July 11, 2026?
The Board approved the acquisition of 100% equity shares of Sushodha Institute of Gastroenterology Private Limited (SIGPL) and a fund-raising Rights Issue of up to Rs. 210 Crores.
What is the total purchase consideration for the SIGPL acquisition?
The total purchase consideration for 100% of SIGPL's equity shares is Rs. 15,48,74,160/-.
How will the SIGPL acquisition consideration be discharged by Arvaya Healthcare?
The purchase consideration will be discharged by issuing up to 38,71,854 fully paid-up equity shares of Arvaya Healthcare at a price of Rs. 40/- per share.
What is the maximum amount Arvaya Healthcare plans to raise through the Rights Issue?
Arvaya Healthcare plans to raise a maximum amount not exceeding Rs. 210 Crores through the Rights Issue of Specified Securities.
What is the cut-off date for E-voting for the postal ballot?
The cut-off date for E-voting for the postal ballot is Friday, July 10, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.